SCHEMBL30145089

SCHEMBL30145089

CCNC(=O)Nc1ccc(-c2ccc(OC)cc2Cl)n2cc(Cc3nc4ccc(Cl)cc4[nH]3)nc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ABL1 P00519 8/20 0.41
▸ MEN1 O00255 1/20 0.37
▸ GAA P10253 1/20 0.37
▸ MAPT P10636 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ PRMT5 O14744 1/20 0.37
▸ FPR2 P25090 1/20 0.37
▸ WDR77 Q9BQA1 1/20 0.37
▸ NTRK1 P04629 2/20 0.37
▸ NTRK2 Q16620 2/20 0.37
▸ AMY1A P0DUB6 1/20 0.37
▸ MAPK1 P28482 1/20 0.36
▸ PIK3CA P42336 1/20 0.36
▸ MAPK8 P45983 1/20 0.36
▸ MAPK9 P45984 1/20 0.36
▸ MAPK10 P53779 1/20 0.36
▸ EGFR P00533 1/20 0.35
▸ ERBB2 P04626 1/20 0.35
▸ MARS2 Q96GW9 2/20 0.35
▸ KDR P35968 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20595586 1.00 ABL1 (0.41) ABL1MEN1GAAMAPTKMT2A
SCHEMBL23419396 0.94 NTRK1 (0.37) ABL1MAPTPRMT5FPR2WDR77
SCHEMBL20595970 0.91 MEN1 (0.39) MEN1GAAMAPTKMT2APRMT5
SCHEMBL20595848 0.91 MEN1 (0.39) MEN1GAAMAPTKMT2APRMT5
SCHEMBL23419287 0.85 MARS2 (0.40) MEN1GAAMAPTKMT2APRMT5
SCHEMBL23419554 0.85 MARS2 (0.38) MEN1GAAMAPTKMT2APRMT5
SCHEMBL20595968 0.82 AMY1A (0.43) MEN1KMT2AAMY1AEGFRERBB2
SCHEMBL20596625 0.81 ABL1 (0.37) ABL1MEN1MAPTKMT2AKDR
SCHEMBL30145306 0.81 ABL1 (0.37) ABL1MEN1MAPTKMT2AKDR
SCHEMBL20596510 0.80 LMNA (0.36) ABL1MEN1GAAMAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11584744-B2 Inhibitors of type 1 methionyl-tRNA synthetase and methods of using them UNIVERSITY OF WASHINGTON (US) 2023-02-21 — — US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11584744-B2 Inhibitors of type 1 methionyl-tRNA synthetase and methods of using them AARS1, EMG1, GARS1 ABL1 1481/4885MEN1 1598/4885GAA 403/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback